PRLD Prelude Therapeutics Incorporated

Prelude is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance.

$7.10  +0.29 (4.26%)
As of 10/04/2022 15:59:50 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/25/2020
Outstanding shares:  47,833,307
Average volume:  67,768
Market cap:   $316,178,159
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKX8YL9
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.23
PS ratio:   0.00
Return on equity:   -45.78%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy